FDA Brief

Warning letters Drugs

FDA warning letter to

Huangshi Hygienic Material Medicine Co., Ltd.

High riskIssued Mar 24, 2025Posted Jun 3, 2025Center for Drug Evaluation and Research (CDER)

Huangshi Hygienic Material Medicine released U.S. drugs without identity and strength testing and lacked stability data for labeled expiration dates.

What happened

FDA inspected the facility from August 26 to 30, 2024, and found that the firm had not performed identity and strength testing of active ingredients before releasing multiple batches for the U.S. market. FDA also found that U.S. product expiration dates were based on stability testing of domestic China products even though the U.S. formulations differed. FDA reviewed the firm’s September 20, 2024 response and found it inadequate.

What FDA found

  1. The firm released drug batches for the U.S. market without testing each batch for identity and strength of active ingredients against final specifications.

    21 CFR 211.165(a)
  2. The firm assigned expiration dates to U.S. products using stability testing for different domestic products, without stability data supporting those U.S. formulations.

    21 CFR 211.137(a)

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days with a corrective action plan, including full testing of retain samples, a remediated stability program, interim measures for products already in the U.S. market, and an independent assessment of test methods. FDA also recommends engaging a qualified CGMP consultant if the firm intends to resume U.S. manufacturing.

Who should pay attention

  • U.S. distributors and retailers selling imported OTC drugs
  • companies buying finished drug products from this manufacturer
  • quality teams overseeing imported drug suppliers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. TSP Solutions Pte. Ltd.

    FDA warns Singapore OTC drug maker TSP Solutions over missing release testing and component identity checks for sunscreens.

    High risk
  2. TCI Co., Ltd BioCosme PABP BRANCH

    FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.

    High risk
  3. PReye, LLC

    FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

    High risk
  4. AHC Products, Inc.

    AHC Products, Inc. was cited for manufacturing-rule violations and unapproved animal drugs, including AniPrin and Rot-B-Gone.

    High risk